comparemela.com

Latest Breaking News On - Annabel clay - Page 1 : comparemela.com

Investegate |Syncona Limited Announcements | Syncona Limited: Gyroscope announces additional positive data

Investegate |Syncona Limited Announcements | Syncona Limited: Gyroscope announces additional positive data
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

London
City-of
United-kingdom
Philadelphia
Pennsylvania
United-states
San-francisco
California
Collins-tim-stamper
Kate-archer
Annabel-clay
Ben-atwell-natalie

Investegate |Syncona Limited Announcements | Syncona Limited: Issue of shares pursuant to incentive scheme

Investegate |Syncona Limited Announcements | Syncona Limited: Issue of shares pursuant to incentive scheme
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United-kingdom
London
City-of
British
Collins-tim-stamper
Martin-murphy
John-bradshaw
Chris-hollowood
Annabel-clay
Ben-atwell-natalie
London-stock-exchange
Syncona-ltd

Investegate |Syncona Limited Announcements | Syncona Limited: Autolus to present additional data in AUTO1

Investegate |Syncona Limited Announcements | Syncona Limited: Director/PDMR Shareholding

Investegate |Syncona Limited Announcements | Syncona Limited: Achilles reports Q1 financial results

  - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -     London, UK 11 May 2021 - Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.   Achilles made significant progress in the first quarter of 2021. We reported the first clinical data from our ongoing CHIRON and THETIS trials evaluating our precision TIL cNeT therapy in patients with non-small cell lung cancer and melanoma, respectively, and priced our successful US initial public offering on Nasdaq, which closed just after quarter-end, said Dr Iraj Ali, Chief Executive Officer of Achilles. We continue to enroll and dose patients and have

United-states
United-kingdom
London
City-of
American
Melissa-gardiner
Collins-tim-stamper
Sukaina-virji
Markwin-velders
Julie-oneill
Miraj-ali
Mary-jane-elliott

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.